INmune Bio to publish video with additional Phase 2 XPro trial findings after AAIC

Inmune Bio, Inc.

Video detailing additional MINDFuL Phase 2 findings of XPro (soluble TNF inhibitor) to be published July 31 at 4 PM ET.
Trial showed consistent cognitive and biomarker benefit after 6 months in amyloid-beta+ patients with ≥2 inflammatory blood biomarkers.
Data presented at AAIC July 29 in Toronto; corporate presentation also filed as Exhibit 99.2.
Dr. Sharon Cohen presented; VP Dr. CJ Barnum cited meaningful changes in short trial.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.